Regulation of ABC Transporters Blood–Brain Barrier

Miller, David S.

doi:10.1016/bs.acr.2014.10.002

Cited by 131 publications

(72 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple ATP-binding cassette (ABC) proteins are expressed on the luminal, blood-facing endothelial plasma membrane of the BBB, which restricts the permeability of large number of toxins including therapeutic agents (Miller, 2015). ABC transporters are ATP-driven efflux pumps for xenobiotics and endogenous metabolites.…”

Section: Cellular Components Of the Bbbmentioning

confidence: 99%

Establishment and Dysfunction of the Blood-Brain Barrier

Zhao

Nelson

Betsholtz³

et al. 2015

Cell

1,301

1,128

View full text Add to dashboard Cite

Structural and functional brain connectivity, synaptic activity and information processing require highly coordinated signal transduction between different cell types within the neurovascular unit and intact blood-brain barrier (BBB) functions. Here, we examine the mechanisms regulating the formation and maintenance of the BBB and functions of BBB-associated cell types. Furthermore, we discuss the growing evidence associating BBB breakdown with the pathogenesis of inherited monogenic neurological disorders and complex multifactorial diseases including Alzheimer’s disease.

show abstract

Section: Cellular Components Of the Bbbmentioning

confidence: 99%

Establishment and Dysfunction of the Blood-Brain Barrier

Zhao

Nelson

Betsholtz³

et al. 2015

Cell

1,301

1,128

View full text Add to dashboard Cite

show abstract

“…The development of PET imaging approaches in humans has raised new opportunities to study P-gp function in situations in which this transporter may be overexpressed (36). Current protocols focusing on influx hindrance require partial P-gp inhibition to achieve substantial 11 C-verapamil baseline K 1 (34,38).…”

Section: Discussionmentioning

confidence: 99%

“…Modulation of P-gp function at the BBB, due to genetic polymorphism (35), environmental factors (36), or drug-drug interactions (37), may contribute to interindividual variability of brain exposure and subsequent pharmacodynamic response to CNS drugs, including pharmacoresistance (36). K 1 is estimated in the early distribution phase, where P-gp works against the concentration gradient between the plasma and the brain (12).…”

Section: Discussionmentioning

confidence: 99%

Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide

Pottier¹,

Marie²,

Goutal³

et al. 2015

J Nucl Med

105

View full text Add to dashboard Cite

The effects of metoclopramide on the central nervous system (CNS) in patients suggest substantial brain distribution. Previous data suggest that metoclopramide brain kinetics may nonetheless be controlled by ATP-binding cassette (ABC) transporters expressed at the blood-brain barrier. We used 11 C-metoclopramide PET imaging to elucidate the kinetic impact of transporter function on metoclopramide exposure to the brain. Methods: 11 C-metoclopramide transport by P-glycoprotein (P-gp; ABCB1) and the breast cancer resistance protein (BCRP; ABCG2) was tested using uptake assays in cells overexpressing P-gp and BCRP. 11 C-metoclopramide brain kinetics were compared using PET in rats (n 5 4-5) in the absence and presence of a pharmacologic dose of metoclopramide (3 mg/kg), with or without P-gp inhibition using intravenous tariquidar (8 mg/kg). The 11 C-metoclopramide brain distribution (V T based on Logan plot analysis) and brain kinetics (2-tissue-compartment model) were characterized with either a measured or an imaged-derived input function. Plasma and brain radiometabolites were studied using radio-high-performance liquid chromatography analysis. Results: 11 C-metoclopramide transport was selective for P-gp over BCRP. Pharmacologic dose did not affect baseline 11 C-metoclopramide brain kinetics (V T 5 2.28 ± 0.32 and 2.04 ± 0.19 mL⋅cm −3 using microdose and pharmacologic dose, respectively). Tariquidar significantly enhanced microdose 11 C-metoclopramide V T (7.80 ± 1.43 mL⋅cm −3 ) with a 4.4-fold increase in K 1 (influx rate constant) and a 2.3-fold increase in binding potential (k 3 /k 4 ) in the 2-tissue-compartment model. In the pharmacologic situation, P-gp inhibition significantly increased metoclopramide brain distribution (V T 5 6.28 ± 0.48 mL⋅cm −3 ) with a 2.0-fold increase in K 1 and a 2.2-fold decrease in k 2 (efflux rate), with no significant impact on binding potential. In this situation, only parent 11 C-metoclopramide could be detected in the brains of P-gp-inhibited rats. Conclusion: 11 C-metoclopramide benefits from favorable pharmacokinetic properties that offer reliable quantification of P-gp function at the blood-brain barrier in a pharmacologic situation. Using metoclopramide as a model of CNS drug, we demonstrated that P-gp function not only reduces influx but also mediates the efflux from the brain back to the blood compartment, with additional impact on brain distribution. This PET-based strategy of P-gp function investigation may provide new insight on the contribution of P-gp to the variability of response to CNS drugs between patients.

show abstract

“…It is known that there are several signaling pathways implicated in the cellular regulation of P-gp and BCRP at the BBB. 36 Thus, even though naloxone is a selective antagonist of the m-opioid receptors, the absence of Pgp and Bcrp upregulation in brain microvessels following the naloxone-precipitated opioid withdrawal may be explained by its effect on other non-opioid receptors, 37,38 which may also be involved in the regulation of these ABC transporters following a morphine chronic treatment. For example, naloxone showed to have a low-affinity for the NMDA receptor in a Xenopus oocytes model.…”

mentioning

confidence: 98%